A Subgroup Analysis of Perioperative Pembrolizumab in Clinical Stage II Non-Small-Cell Lung Cancer from the Randomized KEYNOTE-671 Study
European Journal of Cardio-Thoracic Surgery · 2026
DOI: 10.1093/ejcts/ezag028 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cardio-Thoracic Surgery, 2026. Verfasst von Masahiro Tsuboi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba 277-8577, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc..
Abstract (Originalsprache)
Objectives
Perioperative pembrolizumab plus neoadjuvant chemotherapy significantly improved outcomes versus neoadjuvant chemotherapy alone in early-stage, resectable, non-small-cell lung cancer (NSCLC) in the phase 3 KEYNOTE-671 study. We report outcomes in participants with baseline clinical stage II disease.
Methods
Participants with untreated, resectable, stage II-IIIB (N2) NSCLC were randomized 1:1 to receive pembrolizumab 200 mg or placebo every 3 weeks plus chemotherapy for 4 cycles, followed by surgery and adjuvant pembrolizumab or placebo for 13 cycles (∼9 months). Exploratory analyses were performed in participants with clinical stage II disease.
Results
Of 797 randomized participants, 239 had stage II disease (pembrolizumab plus chemotherapy, n = 118; chemotherapy only, n = 121). Median study follow-up at data cutoff (August 19, 2024) was 49.9 (range, 32.2-75.3) months. Among participants who underwent surgery, 94/99 (94.9%) had R0 resections in the pembrolizumab arm and 89/103 (86.4%) in the neoadjuvant chemotherapy only arm. Event-free survival (hazard ratio [HR], 0.50; 95% CI, 0.34-0.74), overall survival (HR, 0.69; 95% CI, 0.43-1.11), major pathological response (difference, 25.7%; 95% CI, 15.3-35.9), and pathological complete response (difference, 21.3%; 95% CI, 13.2-30.2) were improved in the pembrolizumab arm. Grade 3-4 treatment-related adverse events (AEs) occurred in 50.0% of participants treated with pembrolizumab plus chemotherapy and 40.5% with chemotherapy; no treatment-related AEs led to death.
Conclusions
In participants with stage II NSCLC, perioperative pembrolizumab improved efficacy outcomes with manageable safety versus neoadjuvant chemotherapy alone, consistent with the overall KEYNOTE-671 population. These results support the use of this regimen in patients with stage II disease. Trial Registration ClinicalTrials.gov, NCT03425643, registered/first posted on February 7, 2018 (https://www.clinicaltrials.gov/study/NCT03425643).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba 277-8577, Japan.
- Department of Medicine, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA 94305, United States.
- Department of Medicine, University of Chicago Medicine and Biological Sciences, Chicago, IL 60637, United States.
- Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Department of Oncology No. 1 (Thoracic Surgery), SBHI Leningrad Regional Clinical Hospital, St Petersburg 194291, Russia.
- State Key Laboratory of Molecular Oncology, The First Department of Thoracic Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China.
ORCID-Profile: Heather Wakelee, Hisashi Saji, Benny Weksler, Chien-Sheng Huang, Moishe Liberman
Förderung
- NCI NIH HHS
- Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
Zitieren
APA
Tsuboi, M., Wakelee, H., Garassino, M. C., Gao, S., Luft, A., Chen, K. N., Spicer, J. D., Zhu, Y., Saji, H., Okada, M., Vanakesa, T., Chen, H., Zhao, G., Ikeda, N., Jones, D. R., Weksler, B., Huang, C. S., Jensen, E., Keller, S. M., …, & Liberman, M. (2026). A Subgroup Analysis of Perioperative Pembrolizumab in Clinical Stage II Non-Small-Cell Lung Cancer from the Randomized KEYNOTE-671 Study. European Journal of Cardio-Thoracic Surgery. https://doi.org/10.1093/ejcts/ezag028
Vancouver
Tsuboi M, Wakelee H, Garassino MC, Gao S, Luft A, Chen KN, et al. A Subgroup Analysis of Perioperative Pembrolizumab in Clinical Stage II Non-Small-Cell Lung Cancer from the Randomized KEYNOTE-671 Study. European Journal of Cardio-Thoracic Surgery. 2026. doi:10.1093/ejcts/ezag028
BibTeX
@article{Tsuboi2026,
author = {Tsuboi, Masahiro and Wakelee, Heather and Garassino, Marina C and Gao, Shugeng and Luft, Alexander and Chen, Ke-Neng and Spicer, Jonathan D and Zhu, Yuming and Saji, Hisashi and Okada, Morihito and Vanakesa, Tõnu and Chen, Haiquan and Zhao, Guofang and Ikeda, Norihiko and Jones, David R and Weksler, Benny and Huang, Chien-Sheng and Jensen, Erin and Keller, Steven M and Samkari, Ayman and Liberman, Moishe},
title = {A Subgroup Analysis of Perioperative Pembrolizumab in Clinical Stage II Non-Small-Cell Lung Cancer from the Randomized KEYNOTE-671 Study},
journal = {European Journal of Cardio-Thoracic Surgery},
year = {2026},
doi = {10.1093/ejcts/ezag028}
}
EUVIMED